The companies will produce a domestically manufactured alternative to the immune-regulating cytokine IL-2 in T-cell therapy. Credit: Anusorn Nakdee/Shutterstock.com.

Clinical-stage cell therapy company Shanghai Grit Biotechnology (GRIT) has formed a strategic partnership with Quangang Pharmaceutical (Quangang) to enhance research and development in T-cell therapy for solid tumour patients in China.

The partnership’s primary goal is to develop a globally standardised IL-2 for solid tumour patients undergoing T-cell therapy.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will focus on localising this standard with affordable pricing for Chinese patients.

The collaboration will concentrate on broadening the indications of Quanqi (125SER) Interleukin-2 (IL-2) products for solid tumours.

Quanqi (125SER) is a marketed human Interleukin-2 used in treating solid tumours including renal cell carcinoma, breast cancer, melanoma, bladder cancer, colorectal cancer, liver cancer, lymphoma and lung cancer.

The partnership aims to produce a domestically manufactured alternative to the globally acknowledged immune-regulating cytokine IL-2 in T-cell therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GRIT plans to utilise its extensive experience in T-cell therapy to accelerate the development and commercialisation of cell therapy products through the collaboration.

Both GRIT and Quangang believe that their joint efforts will soon enable a broader range of Chinese patients to access advanced and effective T-cell treatments, along with an affordable local IL-2 product.

GRIT’s non-gene-engineered tumour infiltrating lymphocytes (TILs) programme, GT101, is in a Phase II (pivotal) trial with plans for a biologics licence application (BLA) filing by 2025.

In 2023 Grit secured more than $60m (436.72m yuan) in a Series B funding round to support the development of its pipeline programmes.

China International Capital Corporation led the financing round, which saw investments from Qianhai Ark, Liando Group, Yuanhe Capital and HeFangTian Venture Partnership.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.